Humulin N

Humulin N is a recombinant human insulin (rDNA) marketed as an injectable suspension for subcutaneous use, generally supplied in standard concentrations such as 100 units/mL. It belongs to the human insulin class and is prescribed by healthcare professionals in the European Union for the management of diabetes. The formulation provides a prolonged basal insulin effect to help maintain stable blood glucose levels through consistent absorption over time.

Humulin N is indicated for use as a basal insulin in adults and children with diabetes.

- Long‑acting insulin therapy for Type 1 diabetes mellitus to provide background insulin coverage. - Basal insulin component in combination regimens for Type 2 diabetes mellitus when diet, exercise, and oral agents are insufficient. - Adjunct to rapid‑acting insulin analogues for flexible dosing schedules. - Management of nocturnal hyperglycaemia and fasting glucose levels. - Use in pregnant women with diabetes when benefits outweigh potential risks, under medical supervision.

Like all insulin products, Humulin N may be associated with adverse reactions that vary in frequency and severity.

Common: - Hypoglycemia, which may manifest as sweating, tremor, dizziness, hunger, or confusion, especially if meals are missed or activity is increased. - Mild injection‑site reactions such as pain, redness, swelling, or itching that usually resolve without treatment. - Lipohypertrophy or localized fat atrophy at sites of repeated injections, potentially affecting insulin absorption. - Transient weight gain due to improved glucose utilization and fluid retention.

Serious: - Severe hypoglycemia leading to loss of consciousness, seizures, or the need for emergency assistance. - Allergic reactions ranging from urticaria and angio‑edema to anaphylactic shock, requiring immediate medical care. - Edema or worsening of pre‑existing heart failure, particularly in patients with renal impairment or high sodium intake.

Healthcare providers should evaluate several safety considerations before initiating Humulin N therapy.

- Assess renal and hepatic function, as impairment may prolong insulin action and increase hypoglycemia risk. - Educate patients on recognizing and treating hypoglycemia, including the use of fast‑acting carbohydrates. - Rotate injection sites to reduce lipodystrophy and ensure consistent absorption. - Monitor blood glucose regularly, especially during dose adjustments, illness, or changes in diet and activity. - Use caution in pregnant or breastfeeding women; benefits must outweigh potential risks. - Avoid use in patients with known hypersensitivity to human insulin or any excipients.

Humulin N can interact with other medicines, affecting glucose control or insulin activity.

Avoid: - Concurrent use of other insulin products without proper dose adjustment, which may cause severe hypoglycemia. - Beta‑blockers that mask hypoglycemia symptoms, making detection more difficult. - High‑dose corticosteroids that increase insulin resistance and may require higher insulin doses.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that can potentiate hypoglycemia. - Diuretics, especially thiazides, which may raise blood glucose levels. - ACE inhibitors or ARBs that may enhance insulin sensitivity, potentially lowering glucose further. - Alcohol consumption, which can cause delayed hypoglycemia.